These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26273831)

  • 21. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage.
    Amrite AC; Ayalasomayajula SP; Cheruvu NP; Kompella UB
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):1149-60. PubMed ID: 16505053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Choroidal Thickness Changes After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
    Minnella AM; Federici M; Falsini B; Barbano L; Gambini G; Lanza A; Caporossi A; Savastano MC
    BioDrugs; 2016 Aug; 30(4):353-9. PubMed ID: 27189458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preparation and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(D,L-lactic-co-glycolic acid) microspheres using a double emulsion/solvent evaporation technique.
    Karal-Yılmaz O; Serhatlı M; Baysal K; Baysal BM
    J Microencapsul; 2011; 28(1):46-54. PubMed ID: 21171816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delivery of definable number of drug or growth factor loaded poly(DL-lactic acid-co-glycolic acid) microparticles within human embryonic stem cell derived aggregates.
    Qutachi O; Shakesheff KM; Buttery LD
    J Control Release; 2013 May; 168(1):18-27. PubMed ID: 23500059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration.
    Ahn JK; Moon HJ
    Am J Ophthalmol; 2009 Nov; 148(5):718-724.e1. PubMed ID: 19674731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration.
    Gu X; Yu X; Dai H
    Curr Eye Res; 2014 May; 39(5):518-21. PubMed ID: 24215127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration.
    Grierson R; Meyer-Rüsenberg B; Kunst F; Berna MJ; Richard G; Thill M
    J Ocul Pharmacol Ther; 2013; 29(6):530-8. PubMed ID: 23573802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
    Michels S; Rosenfeld PJ
    Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The results of wet AMD treatment by intravitreal injections--preliminary report].
    Okruszko A; Borucka AI; Ulińska M; Szaflik J
    Klin Oczna; 2007; 109(10-12):389-93. PubMed ID: 18488380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of the efficacy of aflibercept's in the treatment of neovascular age-related macular degeneration in treatment-naive and switched patients. Report of 86 cases].
    Maringe E; Letesson E; Duncombe A; Muraine M; Genevois O
    J Fr Ophtalmol; 2016 Mar; 39(3):255-60. PubMed ID: 26995074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.
    Wang JW; Zhou MW; Zhang X; Huang WB; Gao XB; Wang W; Chen S; Zhang XY; Ding XY; Jonas JB
    Clin Exp Ophthalmol; 2015 Jul; 43(5):415-21. PubMed ID: 25488632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer.
    Kim I; Byeon HJ; Kim TH; Lee ES; Oh KT; Shin BS; Lee KC; Youn YS
    Biomaterials; 2012 Aug; 33(22):5574-83. PubMed ID: 22579235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experimental study on polylactic glycolate acid microparticles with releasing-slowly vascular endothelial growth factor].
    Chen Y; Luo X; Xiao J
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2005 Apr; 19(4):262-3. PubMed ID: 15921313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
    Sawada O; Miyake T; Kakinoki M; Sawada T; Kawamura H; Ohji M
    Retina; 2010; 30(7):1034-8. PubMed ID: 20616682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice.
    Murata N; Takashima Y; Toyoshima K; Yamamoto M; Okada H
    J Control Release; 2008 Mar; 126(3):246-54. PubMed ID: 18215787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ranibizumab for the treatment of neovascular AMD.
    Kaiser PK; Do DV
    Int J Clin Pract; 2007 Mar; 61(3):501-9. PubMed ID: 17313620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
    Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
    BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.